We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Eisai presented data from two Phase III studies of adjunctive therapies for epilepsy—one evaluating the non-inferiority of Zebinix compared to carbamazepine, and an open-label extension study of long-term Fycompa, which demonstrated sustained seizure control for up to two-and-a-half years. The two studies were presented at the European Congress on Epileptology. Read More
Novo Nordisk presented two separate Phase III studies in type 2 diabetes—evaluating semaglutide and Xultophy—at the annual meeting of the European Association for the Study of Diabetes. Read More
Plasma fibrinogen can be used as a biomarker in interventional clinical trials examining patients at high risk for exacerbations or all-cause mortality in chronic obstructive pulmonary disease, according to final guidance to industry issued by FDA. Read More